For many patients with gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) remain the treatment of choice, according to David Armstrong, MA, MB, BChir, FRCP (UK), FRCPC, FACG, AGAF, and colleagues. “However, despite PPI therapy, many patients with GERD continue to be symptomatic,” they write.
Trending
- The GLP-1 Paradox in Colorectal Cancer (Medscape)
- The most pressing workforce issues for 103 healthcare leaders (Becker’s Healthcare)
- FDA-cleared GI test detects ‘most likely causes’ of diarrheal syndromes (Healio)
- A path forward: women in gastroenterology (Gastrointestinal Endoscopy)
- 5 Gastroenterology Headlines You Missed in February 2026 (HCP Live)
- Endoluminal Robotics – what it really is (How to Startup in MedTech)
- AI in GI: A Humanist Approach (GI & Endoscopy News)
- Gastroenterology and private equity in 2026: 5 notes (Becker’s GI & Endoscopy)
